Since the introduction of imatinib mesylate, the role of allogeneic hematopoietic cell transplantation (allo-HCT) for CML has essentially been reserved for patients with advanced disease or imatinib resistance. In addition, there have been concerns regarding imatinib associated cardiac toxicity. We investigated the outcome of 61 patients with CML who received a myeloablative allo-HCT at the University of Minnesota between 1999 and 2006. The median age at HCT was 38.4 (range; 6.9-56.9) years. Thirty-seven patients were in first chronic phase and twenty-four patients in a second chronic or accelerated phase at the time of HCT. Twenty-six patients received imatinib therapy before or after HCT, and thirty-five patients either never received imatinib (n ¼ 32) or received it only at the time of relapse after HCT (n ¼ 3). OS and relapse-free survival (RFS) at 2 years was 69 and 55% for the imatinib group, and 57 and 49% for the non-imatinib group (P ¼ 0.57 and 0.95, respectively). There was no difference in the risk of relapse at 2 years between the groups. Symptomatic cardiac toxicity at 1 year was reported in three imatinib group (12%) and two nonimatinib group (6%) patients (P ¼ 0.44). Thus, patients treated with imatinib either before or after myeloablative allo-HCT had no increase in cardiac toxicity.
Introduction
Imatinib mesylate received FDA approval in 2002 as firstline treatment in patients with CML and as a competitive inhibitor directed toward the abl tyrosine kinase fusion gene found in Philadelphia (Ph þ ) CML. At the gene level, the Ph þ chromosome is created by a translocation of the 5 0 portion of the bcr gene to the kinase domain of the abl gene, creating a fusion protein with unregulated tyrosine kinase activity. 1, 2 Since the introduction of imatinib therapy for the treatment of CML, the need for an allogeneic hematopoietic cell transplant (allo-HCT) has been reserved for those with either advanced disease or resistance to the tyrosine kinase inhibitors imatinib, dasatinib and/or nilotinib. The recent follow-up from the International Randomized Study of Interferon and ST1571 reported an estimated OS at 5 years of 89% for the imatinib cohort. 3 On the basis of these impressive results and those of others, 4, 5 which further confirmed the superiority of imatinib to other therapies (for example, a-IFN, cytarabine), long-term tyrosine kinase inhibitor therapy has since become the gold standard for treatment of CML in first chronic phase (CP1).
Owing to the recent concern that imatinib use may be associated with congestive heart failure (CHF) [6] [7] [8] [9] and that such cardiac toxicity could be further increased during the conditioning therapy received before a myeloablative allo-HCT, 9 we investigated our transplant outcomes and cardiac related toxicities in patients with CML who received a myeloablative allo-HCT since the time imatinib became commercially available.
Patients and methods
Sixty-one patients with Ph þ CML received a myeloablative allo-HCT at the University of Minnesota between 1999 and 2006. The diagnosis of CML was based on the presence of the (9; 22) translocation on standard karyotype analysis, fluorescent in situ hybridization and/or the bcr-abl fusion transcript detected by PCR. All patients and/or guardians gave informed consent before transplant on the Institutional Review Board (IRB) approved treatment protocols. Moreover, this retrospective analysis of patients was approved by the University of Minnesota's institutional review board.
The median age at allo-HCT was 38.4 (range; 6.9-56.9) years. Thirty-seven (60.7%) patients were male. The disease status at the time of allo-HCT was CP1 in 37 patients (60.7%), and second chronic phase or greater (XCP2) or accelerated phase (XAP1) in 24 patients (39.3%). The donor source was HLA-matched sibling's BM or PBSC (n ¼ 27), HLA matched unrelated BM or PBSC (n ¼ 20) or HLA partially matched unrelated umbilical cord blood (UCB) (n ¼ 14). All patients were conditioned with CY (120 mg/kg) and TBI (1320 cGy) with 55 (90.1%) patients receiving cyclosporine-based GVHD prophylaxis and the remaining 6 (9.8%) receiving a T-cell depleted graft. Neutrophil engraftment was defined as two consecutive days with an ANC 4500/ml, and plt recovery was defined as an unsupported plt count 420 000/ml for three consecutive days and seven before plt transfusion-free days.
Twenty-six patients comprising the imatinib group received imatinib therapy either before or after HCT (22 before HCT and 4 after HCT), whereas the remaining thirty-five patients in the non-imatinib group either never received imatinib (n ¼ 32) or received it only at the time of relapse post-HCT (n ¼ 3) (Table 1) . Among the 22 patients treated with imatinib before HCT, 2 received imatinib both before and after HCT, and 3 had imatinib before HCT and again after HCT once relapse was identified. The decision whether or not to initiate imatinib therapy before allo-HCT was determined by the referring physician with the rationale not typically described in the patient's medical record, whereas post-HCT imatinib therapy was decided by the transplant physician at the University of Minnesota and was generally not used as prophylaxis for relapse, although no standard protocol existed at the time. The majority of patients in the non-imatinib group received allo-HCT before 2002 when imatinib therapy was less likely considered standard practice. Imatinib doses ranged from 240 to 340 mg/m 2 /day for the pediatric patients and 400-800 mg/day for adults. When imatinib therapy was initiated after allo-HCT, it began on an average, at day þ 120 (range, 80-180) and continued through day þ 365.
Pre-transplant cardiac function was determined in all patients using both electrocardiogram and echocardiogram, or multiple gated acquisition scan. Therapy related cardiac toxicity was defined as a left ventricular ejection fraction o40%, cardiac hypertrophy or electrocardiogram abnormalities (ST changes, T-wave abnormalities, ischemia and/or infarction) that developed between the time of transplant to 1 year after HCT. All 61 patient charts were reviewed for additional cardiac evaluations or cardiology consultations from the time of allo-HCT to 1 year after HCT to further identify cardiac toxicities that may have been associated with imatinib exposure. Cardiac toxicities were graded according to the National Cancer Institute Common Toxicity Criteria guidelines (NCI CTC version 3.0).
Statistical methods
Four outcome variables were studied: OS, relapse-free survival (RFS), risk of relapse and post-HCT cardiac toxicity comparing the two imatinib use groups. The Kaplan-Meier method was used to estimate OS and RFS, whereas cumulative incidence was estimated for the risk of relapse and cardiac toxicity. The log-rank test was used for comparing the survival estimates and the Gray test for comparing cumulative incidence between the two imatinibuse groups. Multiple regression analysis was conducted for OS, RFS and risk of relapse considering the following factors: imatinib group, age, disease status at time of transplant, stem cell source (including single vs double umbilical cord blood), HLA type, GVHD and GVHD prophylaxis. Specifically, Cox's proportional hazard model was used for OS and RFS, and Fine-Gray model for risk of relapse.
Results
The median time to follow-up for the imatinib and non-imatinib groups was 2.24 (range, 0.65-6.36) and 4.46 (range, 2.0-7.3) years, respectively. There was a longer median time to transplant from initial diagnosis for the Abbreviations: AP ¼ accelerated phase; CP1 ¼ first chronic phase; HCT ¼ hematopoietic cell transplantation. a Among these 22 people, 2 had imatinib both before and after HCT, and 3 had imatinib before HCT and again after relapse (but not post-HCT as prophylaxis).
imatinib group compared with the non-imatinib group (387 vs 170 days, P ¼ 0.003). The median duration of imatinib therapy before HCT for the pre-HCT imatinib group was 9 months (range, 1-60). There was no significant difference between the imatinib and non-imatinib groups with regard to neutrophil engraftment (18 vs 21 days; P ¼ 0.07) or plt recovery (36 vs 36 days; P ¼ 0.94). The cumulative incidence of grade 2-4 acute GVHD at day 100 was lower in the imatinib group (46%) compared with the non-imatinib group (54%), but the difference was not statistically significant (P ¼ 0.61). There was, however, a significant difference in the development of grade 3-4 acute GVHD at day 100 between the imatinib and nonimatinib groups (35, 95% CI; 0.16-0.53) vs (11, 95% CI; 0.01-0.22) (P ¼ 0.02). The cumulative incidence of chronic GVHD at 1 year post-HCT was lower but not significant between the imatinib group (31%) and non-imatinib group (43%) (P ¼ 0.33). Seven patients in the imatinib group died of transplant related causes compared with 12 in the nonimatinib group, providing lower, although not statistically significant, TRM at 2 years in the imatinib group compared with the the non-imatinib group (23 and 37%, respectively; P ¼ 0.28).
Six patients from the imatinib group (21%) and five from the non-imatinib group (14%) have relapsed after HCT (P ¼ 0.41) (Figure 1 ). OS and RFS at 2 years was 69 and 55% for the imatinib group compared with 57 and 49% for the non-imatinib group (P ¼ 0.57 and 0.95, respectively) (Figures 2a and b) .
Multiple regression analysis was conducted for OS, RFS and risk of relapse with imatinib use included in all models. Disease status at the time of HCT (AP/4CP1 vs CP1) was the only factor that significantly affected OS and RFS. Compared with CP1, patients with AP/4CP1 were more likely to have inferior OS and RFS with a hazard ratio (HR) of 4.95 (95% CI; 2.03-12.09, P ¼ 0.0005) and 6.57 (95% CI; 2.82-15.33, Po0.0001), respectively. After adjusting for disease status in the imatinib and nonimatinib groups, the HR was 0.44 (95% CI; 0.18-1.06, P ¼ 0.07) for OS and 0.48 (95% CI; 0.22-1.06, P ¼ 0.07) for RFS. The risk of relapse was not affected by imatinib use (HR ¼ 0.95, P ¼ 0.93) between the imatinib and nonimatinib groups, but was significantly affected by disease status with AP/4CP1 patients more likely to suffer a relapse (HR ¼ 7.94; 95% CI; 1.91-33.05, P ¼ 0.004).
Cardiac function was evaluated before allo-HCT and again at 1 year after HCT. Eighteen patients in total (7 imatinib and 11 non-imatinib) had grade 1-4 cardiac toxicity according to the NCI CTC, with five having clinically significant cardiac toxicities (grade 3 or 4). Three of the twenty-six (12%) patients in the imatinib group had grade 3-4 cardiac toxicity (two patients with infarction and one patient with ischemia) compared with 2 out of 35 (6%) patients in the non-imatinib group (one patient with an ejection fraction o25% and one patient with ischemia) after HCT (P ¼ 0.44) ( Table 2 ). There was no significant difference in cardiac toxicity identified between the imatinib and non-imatinib groups after adjusting for pre-BMT cardiac condition (abnormal vs normal) in multiple regression analysis (Fine-Gray model) with a hazard ratio of 0.60 (P ¼ 0.33). There was no significant difference in exposure to potentially cardiotoxic therapies (anthracyclines, IFN and/or anagrelide) that patients received before allo-HCT, between the imatinib and non-imatinib groups (9/26 (35%) vs 13/35 (37%), respectively, P ¼ 0.84).
Twenty-four of the sixty-one (39%) CML patients had advanced-stage disease (AP or 4CP1) at the time of allo-HCT. Among these advanced-stage patients, fourteen (58%) were in the imatinib group and ten (42%) were in Cumulative incidence of relapse Figure 1 Cumulative incidence of Relapse. The cumulative incidence of relapse for the imatinib and non-imatinib groups at 2 years is 0.21 and 0.14, respectively (P ¼ 0.41). Overall survival
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Relapse-free survival the non-imatinib group. Cardiac toxicity (grades 1-4) was reported in eight of these twenty-four (33%) patients (four imatinib group and four non-imatinib group). Grade 3 or 4 cardiac toxicity was present in three of the four patients in the imatinib group occurring at days þ 94 (ischemia/ infarction), þ 120 (ischemia) and þ 223 (infarction) after HCT, providing a cumulative incidence of 21% at 1 year for the imatinib group and 0% for the non-imatinib group (P ¼ 0.14). However, the competing risk of non-cardiac toxicity mortality at 1 year (taking into account that some patients may not have lived long enough to experience a grade 3 or 4 cardiac toxicity) was significantly greater for the advanced-stage non-imatinib group (0.80; 95% CI; 0.51-1.09) compared with the advanced-stage imatinib group (0.29; 95% CI; 0.04-0.53) (P ¼ 0.004). Considering the two adverse events of grade 3 or 4 cardiac toxicity and mortality simultaneously, the analysis of cardiac toxicityfree survival showed that the advanced-stage imatinib group had a better cardiac toxicity-free survival at 2 years (0.50; 95% CI; 0.23-0.72) than the advanced-stage nonimatinib group (0.10; 95% CI; 0.01-0.36) (P ¼ 0.06) (Figure 3 ).
When analyzing the risk of symptomatic cardiac toxicity in the advanced-stage patients based on pre-HCT imatinib therapy duration, in which the median duration of imatinib before HCT was 9.5 months (range, 1-48), there was no increased risk identified in patients treated longer with imatinib before their myeloablative allo-HCT (HR ¼ 0.95; 95% CI; 0.89-1.00, P ¼ 0.06).
Discussion
With the current recommendation of life-long tyrosine kinase inhibitor therapy for the treatment of CML-CP1, the long-term adverse effects of imatinib assumes great importance. Common toxicities that have been reported with imatinib usage include nausea, vomiting, diarrhea, fatigue, muscle aches, fluid retention and skin rash. 10 The concern that imatinib may lead to more severe toxicities such as CHF has been reported earlier, 7, 8 but gained more significant concern with the publication by Kerkela et al. 6 These investigators described eight patients with CML, median age of 64 (range; 45-76) years, who presented with severe CHF while receiving imatinib therapy. The authors implicated cardiac toxicity as an unanticipated side effect of the c-abl inhibition by imatinib. Although these patients were reported to have no obvious cause for their CHF, they had a history of hypertension (n ¼ 6), diabetes (n ¼ 3) and coronary artery disease (n ¼ 3).
The concern of imatinib related cardiac toxicity in the non-HCT setting has since been addressed by several investigators. [11] [12] [13] In each of these reports, cardiac failure and left ventricular dysfunction, which was possibly or probably related to imatinib therapy, were either not identified 11 or were found to occur rarely (0.04%/year) as in the International Randomized Study of Interferon and ST1571 trial. 12 Atallah et al. 13 recently reviewed over 1200 CML patients treated with imatinib and reported the presence of CHF in 22 of the 1276 (1.7%) patients. These 22 patients had a median age of 68 (range; 50-83) years with eighteen (82%) having an earlier diagnosed cardiovascular illness leaving the authors to conclude that although the potential of cardiac related toxicity does exist while on imatinib, it is a rare event mainly seen in elderly patients with a pre-existing cardiac condition. Since the original report by Kerkela et al., there has been no further evidence to support an increased risk of cardiac toxicity with imatinib. Whether or not imatinib exposure can further affect cardiac related toxicities that may accompany a myeloablative allo-HCT in CML remains uncertain.
No large study has been published reporting the impact imatinib may have on the cardiac status of patients receiving a myeloablative allo-HCT for CML. There was a brief report by Sohn et al. 9 identifying two accelerated phase CML patients, ages 29 and 33 years, treated with imatinib therapy before a myeloablative allo-HCT who later developed CHF at days þ 5 and þ 27 after HCT. These two patients, conditioned with BU and CY, were compared with 45 non-imatinib treated leukemia patients who received identical conditioning for an allo-HCT and did not develop cardiac failure. The authors concluded that myeloablative allo-HCT for advanced-stage CML may Non-imatinib group
Imatinib group
P=0.06 Figure 3 Cumulative incidence for cardiac-toxicity-free survival in patients with AP (accelerated phase)/4CP1 (first chronic phase) CML. The cumulative incidence for cardiac-toxicity-free survival in patients with advanced-stage disease (AP/4CP1) for the imatinib and non-imatinib groups at 2 years is 0.50 and 0.10, respectively (P ¼ 0.06).
increase the risk for cardiac failure in patients who had undergone imatinib therapy earlier.
In order to further investigate the concerns raised by Kerkela and Sohn et al., we evaluated the frequency of cardiac toxicity in patients who had undergone a myeloablative allo-HCT and received imatinib in either the pre-or post-HCT setting at the University of Minnesota between 1999 and 2006. The median age of our cohort was younger than that reported by Kerkela and Atallah et al. (38 vs 64 and 68 years, respectively) but similar to the report by Sohn et al. The incidence of symptomatic cardiac toxicity was found to be greater in the imatinib group compared with that in the non-imatinib group (12 vs 6%) at 1 year post-HCT. Although this difference did not reach statistical significance, our relatively small sample size limited our power to show a difference. Overall, in this heterogeneous group of 61 CML patients who underwent allo-HCT at our institution, we did not find a significant increased risk of cardiac toxicity associated with imatinib use.
When analyzing the advanced-stage CML patients, we identified 24 patients with advanced stage disease (AP or 4CP1) with 8 of the 24 (33.3%) reporting cardiac toxicity. Of these eight patients, only three were considered to have significant symptomatic cardiac toxicity (NCI CTC Grade 3-4), which were all reported in the imatinib group. All three of these imatinib group patients received pre-HCT imatinib with one receiving additional imatinib therapy at the time of relapse after HCT. The reported cardiac toxicities tended to be ischemic in nature and, therefore, may have been the result of atherosclerotic coronary artery deterioration from their radiation exposure during the transplant conditioning, 14 and/or cyclosporineassociated hyperlipidemia and/or hypertension, 15 rather than the effect of c-abl inhibition by imatinib on cardiac myocytes, which, theoretically, would result in nonischemic cardiac injury. As the advanced-stage imatinib group tended to outlive the non-imatinib group, cardiac toxicity is less likely to be detected in the latter group, which had a greater chance of dying before developing such toxicities. It is interesting to note that among the advanced-stage imatinib group patients, those who received a longer duration of imatinib therapy before HCT trended toward a lower chance of developing grade 3 or 4 cardiac toxicity.
In terms of non-cardiac transplant outcomes, we observed a greater incidence of acute GVHD (grade 3-4) and a trend toward less chronic GVHD in the imatinib group compared with that in the non-imatinib group. There have been earlier reports describing lower incidences of chronic GVHD in patients who received imatinib therapy earlier, [16] [17] [18] [19] but as for imatinib increasing the incidence of severe acute GVHD (grade 3-4), the literature does not support our finding. These results may have been affected by our relatively small sample size. The reason imatinib may alter the development of GVHD is unclear, but could be related to its ability to inhibit T-cell proliferation, TCRmediated T-cell activation and/or DC activation/function. 20, 21 The effect imatinib had on the major transplant outcomes (OS, RFS and risk of relapse) for our CML cohort was not statistically significant and was in agreement with earlier reports. 18, 19, 22 Limitations to this study exist in the lack of standard dosing and/or timing of imatinib therapy in our patients both before and after HCT, the heterogeneous nature and overall small number of patients evaluated and our limited power to observe a difference in cardiac event rates. Despite these limitations, on the basis of this retrospective analysis of a heterogeneous group of CML patients, imatinib use in the peri-transplant period had no effect on either TRM or cardiac toxicity. Although, imatinib related cardiac toxicity was not reported as a cause of mortality in our patients, caution should be taken in patients with either advanced stage CML or an earlier history of cardiac disease that are treated with imatinib in the peri-transplant period, regarding their potential for developing cardiac toxicity after a myeloablative allo-HCT. A larger prospective study of CML patients in the myeloablative setting will be necessary to ultimately determine imatinib's association with cardiac toxicity when used in the peri-transplant period.
